What Researchers Did
Researchers reviewed evidence from 1986 to 2002 regarding the pharmacological management of arousal states and neurological sequelae in patients with acute or chronic head injuries.
What They Found
The review examined the evidence for psychostimulants, antidepressants, Parkinson's medications, anticonvulsants, modafinil, lactate, hyperbaric oxygen, electroconvulsive therapy, and transmagnetic stimulation. They found that the quality of evidence for these treatments was generally poor and often conflicting, resulting in indecisive guidelines for patient care.
What This Means for Canadian Patients
Canadian patients recovering from head injuries may encounter challenges in treatment decisions due to the lack of robust, clear evidence for many awakening agents. Clinicians must carefully weigh the limited available evidence and individual patient needs when managing post-head injury neurocognitive, neurobehavioural, and neuropsychiatric symptoms.
Canadian Relevance
This clinical guideline directly addresses the serious burden of brain injuries in Canada and was published in a Canadian journal, making its findings highly relevant to Canadian healthcare providers and patients.
Study Limitations
A significant limitation was the generally poor and conflicting quality of the existing evidence, which led to indecisive treatment guidelines and did not include all potential therapeutic agents.